In a previous posting, we flagged how the BIOSECURE Act (enacted as Section 851 of the Fiscal Year 2026 National Defense Authorization Act) reflects a growing focus on biotechnology supply chains within federal procurement. The statute is designed around a simple premise: Biotechnology risks rarely appear at the level of the final product. Instead, the risks tend to emerge through tools, platforms, and service providers embedded in the performance of federally funded work.
Nowhere is that observation more apparent than in industries adjacent to biotechnology that rely heavily on biological data, specialized testing infrastructure, or outsourced research capabilities. Examples include pharmaceutical and biologics developers, medical device and diagnostics manufacturers, contract research organizations (CROs) and specialized laboratory providers, healthcare and academic research institutions participating in federally funded programs, and technology companies supporting biological data analytics or laboratory automation. For these sectors, biotechnology may not define the business model, but it plays a quiet yet significant operational role in how products are discovered, validated, and manufactured. The BIOSECURE Act brings those operational dependencies into sharper focus.
Continue Reading The BIOSECURE Act and the Expanding Life Sciences Supply Chain: Practical Considerations for Research-Driven Industries